Higher cortical and lower subcortical metabolism in detoxified methamphetamine abusers.
暂无分享,去创建一个
J S Fowler | N. Volkow | L. Chang | Gene-Jack Wang | J. Fowler | G. Wang | J. Logan | Christopher T. Wong | Yu-Shin Ding | R. Hitzemann | S. Gatley | Y. Ding | C. Wong | D. Franceschi | M. Sedler | L Chang | J Logan | D Franceschi | N D Volkow | Y S Ding | G J Wang | R Hitzemann | S J Gatley | M J Sedler | C Wong | R. Hitzemann | Linda Chang | Linda Chang | Christopher Wong
[1] D. Kuhl,et al. Neurochemical imaging of Alzheimer's disease and other degenerative dementias. , 1998, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.
[2] Linda Chang,et al. Evidence for long-term neurotoxicity associated with methamphetamine abuse , 2000, Neurology.
[3] Mathias Schreckenberger,et al. Neurometabolic Effects of Psilocybin, 3,4-Methylenedioxyethylamphetamine (MDE) and d-Methamphetamine in Healthy Volunteers A Double-Blind, Placebo-Controlled PET Study with [18F]FDG , 1999, Neuropsychopharmacology.
[4] J. Larsen,et al. The influence of fatigue on health‐related quality of life in patients with Parkinson's disease , 2003, Acta neurologica Scandinavica.
[5] N. Volkow,et al. Addiction and imaging of the living human brain. , 1998, Drug and alcohol dependence.
[6] L. Radloff. The CES-D Scale , 1977 .
[7] P. Groves,et al. Histological and ultrastructural evidence thatd-amphetamine causes degeneration in neostriatum and frontal cortex of rats , 1990, Brain Research.
[8] Karl J. Friston,et al. Statistical parametric mapping in functional neuroimaging: beyond PET and fMRI activation studies. , 1998, European journal of nuclear medicine.
[9] M. Pallàs,et al. Microgliosis and down-regulation of adenosine transporter induced by methamphetamine in rats , 1998, Brain Research.
[10] D. Brooks. The early diagnosis of parkinson's disease , 1998, Annals of neurology.
[11] Seiden Ls,et al. Methamphetamine and methylenedioxymethamphetamine neurotoxicity: possible mechanisms of cell destruction. , 1996 .
[12] L. Seiden,et al. Long-term effects of repeated methylamphetamine administration on monoamine neurons in the rhesus monkey brain , 1985, Brain Research.
[13] D. Brunswick,et al. Effects of high‐dose methamphetamine on monoamine uptake sites in rat brain measured by quantitative autoradiography , 1992, Synapse.
[14] T. Ishikawa,et al. The Metabolic Topography of Parkinsonism , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[15] L. Cervo,et al. Effects of repeated methamphetamine administration on methamphetamine self-administration in rhesus monkeys , 1984, Pharmacology Biochemistry and Behavior.
[16] D. Hovda,et al. Administration of Excitatory Amino Acid Antagonists via Microdialysis Attenuates the Increase in Glucose Utilization Seen following Concussive Brain Injury , 1992, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[17] S. Walsh,et al. Motor impairments after methamphetamine-induced neurotoxicity in the rat. , 1992, The Journal of pharmacology and experimental therapeutics.
[18] J. Cadet,et al. Methamphetamine (METH) causes reactive gliosis in vitro: attenuation by the ADP-ribosylation (ADPR) inhibitor, benzamide. , 1994, Life sciences.
[19] M. Lee,et al. A case of central pontine and extrapontine myelinolysis with early hypermetabolism on 18FDG-PET scan. , 1998, Journal of Korean medical science.
[20] C. Meshul,et al. High-dose methamphetamine treatment alters presynaptic GABA and glutamate immunoreactivity , 1999, Neuroscience.
[21] W. Hays. Statistics for the social sciences , 1973 .
[22] J O Rinne,et al. Usefulness of a dopamine transporter PET ligand [18F]β-CFT in assessing disability in Parkinson's disease , 1999, Journal of neurology, neurosurgery, and psychiatry.
[23] L. Seiden,et al. α-Methyltyrosine blocks methylamphetamine-induced degeneration in the rat somatosensory cortex , 1986, Brain Research.
[24] F. Fazio,et al. Differential distribution of striatal [123I]β-CIT in Parkinson’s disease and progressive supranuclear palsy, evaluated with single-photon emission tomography , 1998, European Journal of Nuclear Medicine.
[25] N. Alpert,et al. FDG hypermetabolism associated with inflammatory necrotic changes following radiation of meningioma. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[26] A. Alavi,et al. Metabolic and clinical correlates of acute ischemic infarction , 1987, Neurology.
[27] Richard S. J. Frackowiak,et al. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C‐raclopride and positron emission tomography , 1992, Annals of neurology.
[28] S. Tsai,et al. Effects of Repeated High-Dose Methamphetamine on Local Cerebral Glucose Utilization in Rats , 1999, Neuropsychopharmacology.
[29] L. Matsuda,et al. Neurotoxicity of amphetamines and their metabolites. , 1997, NIDA research monograph.
[30] V. Dhawan,et al. Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET , 1998, Movement disorders : official journal of the Movement Disorder Society.
[31] A. Levey,et al. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users , 1996, Nature Medicine.
[32] K. Shaw. Human methamphetamine-related fatalities in Taiwan during 1991-1996. , 1999, Journal of forensic sciences.
[33] M. Sasaki,et al. Hyperperfusion and hypermetabolism in brain radiation necrosis with epileptic activity. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[34] D. Wong,et al. Reduced Striatal Dopamine Transporter Density in Abstinent Methamphetamine and Methcathinone Users: Evidence from Positron Emission Tomography Studies with [11C]WIN-35,428 , 1998, The Journal of Neuroscience.
[35] L. Seiden,et al. Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: A regional study , 1980, Brain Research.
[36] D. Mash,et al. Immunochemical analysis of dopamine transporter protein in Parkinson's disease , 1997, Annals of neurology.
[37] G Lucignani,et al. Fluorine-18-fluorodeoxyglucose PET to determine regional cerebral glucose utilization: a re-examination. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[38] C. Vorhees,et al. Effect of methamphetamine on glutamate‐positive neurons in the adult and developing rat somatosensory cortex , 1996, Synapse.
[39] S. O'dell,et al. Striatal and cortical NMDA receptors are altered by a neurotoxic regimen of methamphetamine , 1996, Synapse.